Breaking: UN Demands Answers From Namibia on Toxic Legacy of Copper Smelter

After inaccurate readings from Dexcom’s flagship G7 device, some diabetics are ending up in the ICU — or dead. A surprise FDA inspection revealed Dexcom made an unauthorized design change to a key component of the G7 that internal studies showed was inferior by “every accuracy metric.” Dexcom sold the “adulterated” device anyway. Then several execs fled amid FDA scrutiny, soaring complaints, rising competition, insiders dumping $DXCM, and questionable accounting. Patients are now returning to the G6 or switching to competitors. This investigation reveals Dexcom’s problems are far worse than previously known. It also tackles the mystery: How did a great innovator lose its way — and the trust of diabetics across America?
On The B-2s Headed West — And East
It seems their best idea is $750 gift cards that residents have called a “joke” and “insult.”
Breaking News & Investigations.
Right to Your Inbox.
No Paywalls.
No Ads.